Unleashing Canada’s Radiopharmaceutical Excellence

The CPDC-adMare Radiopharmaceutical Initiative (CARI)

CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) where we will bring respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain considerable global competitive advantage: RADIOPHARMACEUTICALS. The objective of CARI is for CPDC and adMare to seek out and uncover radiopharmaceutical opportunities arising from academic discoveries and early enterprises, establish rigorous drug development programs around selected opportunities, and drive the generation of proof-of-principle and other data supportive of the commercialization of new radiopharmaceutical assets.

Program Offerings:

Biologics Validation & Support

  • In vivo & in vitro evaluation of molecular targets
  • Antibody/peptide/vector development, characterization & binding
  • Internalization protocols & assays
  • Conjugation of various chelators

Chemistry Manufacturing & Controls

  • Lead compound optimization
  • Process development & validation
  • Analytical & bioanalytical method
  • Drug product formulation

Radiochemistry Research Consultation

  • Radiolabelling with diagnostic & therapeutics isotopes
  • Separation & purification strategies

Regulatory Affairs

  • Regulatory strategy
  • Preparation & management of regulatory submissions
  • Drug development plans
  • Preparation of clinical trials documentation
  • Management of consultation meetings with regulator

Business Development

  • Market research & analysis
  • Business plan & marketing strategy development
  • Partnership development

Commercialization & IP Strategies

  • Third-party management
  • Scale-up synthesis support
  • Quality control processes and strategies

Click here to apply.

To learn more about CARI please:

About the Centre for Probe Development and Commercialization (CPDC):

The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca or contact info@imagingprobes.ca

For additional information, please contact:

Stuart Cain
Associate Director, Scientific Evaluation
adMare BioInnovations
scain@admarebio.com

Ghadeer Shubassi
Business Development Manager
The Centre for Probe Development and Commercialization (CPDC)
shubassi@imagingprobes.ca
289-683-0870